Seven Eight Capital, LP Seagen Inc. Transaction History

Seven Eight Capital, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$117.37 - $139.17 $3.67 Million - $4.35 Million	-31,266 Reduced 74.02%	10,975 $1.41 Million
Q3 2022 Nov 10, 2022	BUY	$135.27 - $180.11 $4.39 Million - $5.85 Million	32,464 Added 332.04%	42,241 $5.78 Million
Q2 2022 Aug 04, 2022	BUY	$108.81 - $179.33 $1.06 Million - $1.75 Million	9,777 New	9,777 $1.73 Million
Q1 2022 May 11, 2022	SELL	$119.61 - $157.85 $160,755 - $212,150	-1,344 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$142.57 - $190.86 $612,908 - $820,507	-4,299 Reduced 76.18%	1,344 $208,000
Q3 2021 Nov 15, 2021	SELL	$142.45 - $169.82 $1.55 Million - $1.85 Million	-10,885 Reduced 65.86%	5,643 $958,000
Q2 2021 Aug 13, 2021	BUY	$135.08 - $161.1 $2.23 Million - $2.66 Million	16,528 New	16,528 $2.61 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Seven Eight Capital, LP with notifications on news.